Author: Ravi Shankar

SAN CARLOS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) — Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that it will present new clinical, translational, and preclinical data across its pipeline at the European Academy of Dermatology and Venereology (EADV) Congress 2026 and the Fall Clinical Dermatology Conference (FCD) 2026.

Attovia will present four posters: three on ATTO-1310, a next generation anti-IL-31 ATTOBODY-based therapeutic, and one on ATTO-2306, a novel long-acting anti-IL-31 and IL-13 bispecific. The ATTO-1310 posters will highlight Phase 1a data in healthy volunteers, translational data advancing the understanding of IL-31 across pruritic skin diseases, and interim Phase 1b data in patients with high-itch atopic dermatitis (AD) or with chronic pruritus. The ATTO-2306 poster will feature new preclinical data.

The EADV Congress 2026 will take place September 30 – October 3, 2026 in Vienna, Austria and FCD 2026 will take place on October 8-11, 2026 in Las Vegas, Nevada. Presentation details are below.

ATTO-1310

• EADV 2026 Poster Presentations
  • Title: Safety, Pharmacokinetics, and Pharmacodynamics of ATTO-1310, a Novel Anti-IL-31 ATTOBODY-Fc Fusion Protein, in Healthy Adults (Abstract: AS-1248)
  • Title: Ultra-Sensitive Detection of Circulating IL-31 Reveals Elevated Levels Across Pruritic Skin Diseases (Abstract: AS-3150)
• FCD 2026 Poster Presentation
  • Title: Efficacy and Safety of a Single Dose of ATTO-1310, a Novel Anti-IL-31 ATTOBODY-Fc Fusion Protein: Interim Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study in Patients with Atopic Dermatitis or with Chronic Pruritus

ATTO-2306

• FCD 2026 Poster Presentation
  • Title: Preclinical Characterization of ATTO-2306, a Long-Acting Bispecific Antibody Targeting IL-13 and IL-31 for Type 2 Inflammatory Skin Diseases

Following each congress, the posters will be available on the Publications page of the Attovia website at https://www.attovia.com.

About Attovia Therapeutics, Inc.
Attovia™ is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need. All of its product candidates have been internally discovered using its ATTOBODY™ biparatopic biologics platform. Attovia’s ATTOBODY platform uses an evolution-driven, high-throughput process that allows for rapid discovery and creation of a high diversity of potential product candidates.

Attovia’s lead programs include ATTO-1310, an anti-IL-31 ATTOBODY-based therapeutic in clinical development for chronic pruritic diseases; ATTO-2306, a long-acting bispecific antibody targeting IL-31 and IL-13 in IND-enabling studies for atopic dermatitis and other immune-mediated skin diseases; and ATTO-1091, a trispecific antibody targeting TL1A, IL-23p19, and integrin α4β7 in IND-enabling studies for inflammatory bowel disease. Attovia’s other programs include highly innovative conditional ‘AND’ gated bispecific immune cell survival blockers and multispecifics.

Investor and Media Contact

Attovia Therapeutics
ir@attovia.com

PJ Kelleher
LifeSci Advisors LLC
617-430-7579
pkelleher@lifesciadvisors.com

MALMÖ, Sweden, September 28, 2026 – Oatly Group AB (publ) (Nasdaq: OTLY), the world’s original and largest oat drink company, will report financial results for the third quarter ended September 30, 2026, on Wednesday October 28, 2026 before the U.S. market opens. Oatly will host a conference call and webcast at 8:00 a.m. ET on the same day to discuss the results.

The conference call and simultaneous live webcast can be accessed on Oatly’s Investors website at https://investors.oatly.com under “Events.” The webcast will be archived for 30 days.

About Oatly

We are the world’s original and largest oat drink company. For over 30 years, we have exclusively focused on developing expertise around oats: a global power crop with inherent properties. Our commitment to oats has resulted in core technical advancements that enabled us to unlock the breadth of the dairy portfolio, including alternatives to milks, ice cream, yogurt, cooking creams, spreads and on-the-go drinks. Headquartered in Malmö, Sweden, the Oatly brand is available in more than 60 countries globally.

For more information, please visit www.oatly.com.

Contacts
investors@oatly.com
press@oatly.com

DALLAS, Sept. 28, 2026 (GLOBE NEWSWIRE) — Applied Digital Corporation (Nasdaq: APLD) (“Applied Digital” or the “Company”), a U.S.-based designer, developer, owner, and operator of large-scale, purpose-built data centers engineered to support high-performance computing (“HPC”) workloads, including artificial intelligence (“AI”), machine learning, and other accelerated-compute applications, will host a conference call on Wednesday, October 7, 2026, at 5:00 p.m. Eastern Time to discuss its operations and financial results for the fiscal first quarter ended August 31, 2026. A press release detailing these results will be issued after the market closes on the same day.

Applied Digital management will provide prepared remarks, followed by a question-and-answer period.

Date: Wednesday, October 7, 2026
Time: 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time)
North America Dial-In: 1-833-461-5787
International Dial-In: +1 (585) 542-9983
Conference ID: 153 131 451

Please call the conference telephone number approximately 10 minutes before the start time. An operator will register your name and organization. If you have difficulty connecting with the conference call, please get in touch with Applied Digital’s investor relations team at 1-949-574-3860.

The conference call will also be broadcast live and available for replay for one year here.

About Applied Digital
Applied Digital Corporation (Nasdaq: APLD) named Best Data Center in the Americas 2025 by Datacloud – designs, develops, owns, and operates large-scale, purpose-built data centers engineered to support HPC workloads, including AI, machine learning, and other accelerated-compute applications. Headquartered in Dallas, TX, and founded in 2021, the Company combines hyperscale expertise, closed-loop cooling, and rapid deployment capabilities to deliver secure, scalable compute at industry-leading speed and efficiency, while creating economic opportunities in underserved communities through its award-winning Polaris Forge AI Factory model.

Find more information at www.applieddigital.com. Follow us on X (formerly Twitter) at @APLDdigital.

Caution About Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance, product development, market position, business strategy and objectives and future financing plans. These statements use words, and variations of words, such as “will,” “continue,” “build,” “future,” “increase,” “drive,” “believe,” “look,” “ahead,” “confident,” “deliver,” “outlook,” “demonstrates,” “expect,” “project” and “predict.” Other examples of forward-looking statements may include, but are not limited to, (i) statements that reflect perspectives and expectations regarding the lease agreements and current and future campus development, (ii) statements about the HPC industry, (iii) statements of Company plans and objectives, including our evolving business model, or estimates or predictions of actions by suppliers and current and potential customers, (iv) statements of future economic performance, and (v) statements of assumptions underlying other statements and statements about the Company or its business. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events and thus are inherently subject to uncertainty. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the Company’s expectations and projections. These risks, uncertainties, and other factors include: our ability to complete construction of our data centers; changes to AI and HPC infrastructure needs and their impact on future plans; risks associated with the leasing business, including those associated with counterparties; costs related to the HPC operations and strategy; our ability to timely deliver any services required in connection with completion of installation under our lease agreements; our ability to raise additional capital to fund ongoing and future data center construction and operations; our ability to obtain financing of the lease agreements on acceptable financing terms, or at all; our dependence on principal customers, including our ability to execute and perform our obligations under our leases with key customers, including without limitation, the lease agreements; our ability to timely and successfully build hosting facilities with the appropriate contractual margins and efficiencies; power or other supply disruptions and equipment failures; the inability to comply with regulations, developments and changes in regulations; cash flow and access to capital; availability of project and other financing to continue to grow our business; decline in demand for our products and services; maintenance of third party relationships; and conditions in the debt and equity capital markets. A further list and description of these risks, uncertainties and other factors can be found in the company’s most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q, including in the sections captioned “Forward-Looking Statements” and “Risk Factors,” and in the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, on the Company’s website (www.applieddigital.com) under “Investors,” or on request from the Company. Information in this release is as of the dates and time periods indicated herein, and the Company does not undertake to update any of the information contained in these materials, except as required by law.

Investor Relations Contacts
Matt Glover and Ralf Esper
Gateway Group, Inc.
(949) 574-3860
APLD@gateway-grp.com

Media Contact
JSA (Jaymie Scotto & Associates)
(856) 264-7827
jsa_applied@jsa.net

Dynamic Fleet Growth on Track

Five New-Technology Panamaxes on Order

Tanker Market Fundamentals Remain Strong

ATHENS, Greece, Sept. 28, 2026 (GLOBE NEWSWIRE) — TEN, Ltd. (NYSE: TEN) (the “Company”) today reported the sale of the oldest vessel in its fleet, the 2003 Japanese-built Panamax tanker Andes, to independent third parties. The sale generated approximately $13.0 million of free cash and registered a $4.6 million capital gain, to be recorded in the third quarter of 2026.  

“The Company has embarked on a significant fleet growth program, as reflected in its 26-vessel orderbook, of which seven vessels have already been delivered. Particular emphasis has been placed on the flexible Panamax segment through the construction of five units,” Mr. George Saroglou, President of TEN commented. “Looking ahead, we will continue to evaluate sale and purchase opportunities while remaining committed to maintaining fleet modernity and operational flexibility that have allowed TEN to thrive through market cycles over the decades,” Mr. Saroglou concluded.

TEN’s CURRENT NEWBUILDING PROGRAM

#	Name	Type	Delivery (exp)	Status	Employment
CONVENTIONAL TANKERS
1	DR IRENE TSAKOS	Suezmax – Scrubber Fitted	Q2 2025	DELIVERED	Yes
2	SILIA T	Suezmax – Scrubber Fitted	Q4 2025	DELIVERED	Yes
3	DELOS T	MR – Scrubber Fitted	Q1 2026	DELIVERED	Yes
4	DION	MR – Scrubber Fitted	Q1 2026	DELIVERED	Yes
5	AMAZONA	Panamax LR1 – Scrubber Fitted	Q2 2027	Under Construction	TBA
6	MAYA	Panamax LR1 – Scrubber Fitted	Q3 2027	Under Construction	TBA
7	INCA	Panamax LR1 – Scrubber Fitted	Q4 2027	Under Construction	TBA
8	CHAIRMAN DJS	VLCC – Scrubber Fitted	Q4 2027	Under Construction	TBA
9	TBN	VLCC – Scrubber Fitted	Q1 2028	Under Construction	TBA
10	TBN	VLCC – Scrubber Fitted	Q2 2028	Under Construction	TBA
11	AZTEC	Panamax LR1 – Scrubber Fitted	Q3 2028	Under Construction	TBA
12	ANDES	Panamax LR1 – Scrubber Fitted	Q3 2028	Under Construction	TBA
SHUTTLE TANKERS
13	ATHENS 04	DP2 Shuttle Tanker	Q2 2025	DELIVERED	Yes
14	PARIS 24	DP2 Shuttle Tanker	Q3 2025	DELIVERED	Yes
15	ANFIELD DP	DP2 Shuttle Tanker	Q3 2026	DELIVERED	Yes
16	ARIANO SUASSUNA DP	DP2 Shuttle Tanker	Q3 2027	Under Construction	Yes
17	ELZA SOARES DP	DP2 Shuttle Tanker	Q4 2027	Under Construction	Yes
18	MARIA FIRMINA DP	DP2 Shuttle Tanker	Q1 2028	Under Construction	Yes
19	CAROLINA DE JESUS DP	DP2 Shuttle Tanker	Q2 2028	Under Construction	Yes
20	DR SOCRATES DP	DP2 Shuttle Tanker	Q3 2028	Under Construction	Yes
21	MARACANA DP	DP2 Shuttle Tanker	Q3 2028	Under Construction	Yes
22	CORINTHIANS DP	DP2 Shuttle Tanker	Q4 2028	Under Construction	Yes
23	IPANEMAS DP	DP2 Shuttle Tanker	Q4 2028	Under Construction	Yes
24	COPA DP	DP2 Shuttle Tanker	Q4 2028	Under Construction	Yes
LNG CARRIERS
25	NY ENERGY 26	LNG Carrier	Q3 2028	Under Construction	TBA
26	TBN	LNG Carrier	Q1 2029	Under Construction	TBA

ABOUT TEN LTD.
Founded in Bermuda in 1993 and celebrating 33 years as a public company, 24 of which on the NYSE, TEN is one of the first and most established public shipping companies in the world. TEN’s diversified pro-forma energy fleet currently consists of 80 vessels, totaling approx. 10.4 million dwt.

ABOUT FORWARD-LOOKING STATEMENTS
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those predicted by such forward-looking statements. TEN undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For further information, please contact:

Tsakos Energy Navigation Ltd.
George Saroglou
President & COO
+30210 94 07 710
gsaroglou@tenn.gr

Investor Relations / Media
Capital Link, Inc.
Nicolas Bornozis/ Markella Kara
+212 661 7566
ten@capitallink.com

Seasoned technology executive to lead Adeia’s continued growth; succeeds Paul E. Davis, who announced in May 2026 his intention to step down after 15 years with the company

SAN JOSE, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) — Adeia Inc. (Nasdaq: ADEA), the technology company pioneering foundational innovations that shape how the world computes, connects, and experiences entertainment, today announced that its board of directors (the “Board”) has appointed Dipti Vachani as chief executive officer, effective October 12, 2026. Vachani will also join the Board, effective the same day. She succeeds Paul E. Davis, who in May 2026 informed the company of his intention to step down as chief executive officer and member of the Board to focus on his health and personal pursuits. Davis has agreed to serve in an advisory capacity through the end of the year to support a smooth transition.

Vachani brings to Adeia a tremendous wealth of broad leadership experience, technical credibility and meaningful partnerships, developed over nearly 30 years in the semiconductor industry. She has deep expertise in semiconductor ecosystems, advanced computer architectures, AI infrastructure, and long-cycle commercial relationships with demonstrated success expanding global businesses into new sectors.

Vachani most recently served as senior vice president, general manager, Automotive Business Unit for Arm Limited, a position she held from 2018 until 2026, where she successfully developed market specific IP programs into new, high-value recurring revenue streams. She also helped develop Arm Total Access and Arm Flexible Access, expanding IP utilization across the licensee base, and founded the SOAFEE Alliance, which today includes more than 200 member companies. From 2015 to 2018, Vachani was vice president, general manager of Intel Corporation’s Internet of Things Group. Prior to Intel, Vachani was vice president, general manager, Power, Lighting and Display at Skyworks Solutions beginning in 2013. Before Skyworks, Vachani held various program and product line positions at Texas Instruments, Inc. ending as vice president, general manager, Single Core Processors.

Vachani served as a member of the board of directors of Axcelis Technologies, Inc., a publicly traded semiconductor equipment manufacturer, from 2022 to 2025. Vachani earned a Bachelor of Science degree in Computer Engineering from Texas A&M University and an Executive M.B.A. from The University of Texas at Austin.

The Board selected Vachani for her proven track record and commitment to innovation to build upon Adeia’s successful transformation. She will continue the focus on strengthening our technology leadership in the semiconductor and media markets, diversifying our recurring revenue streams beyond Pay-TV, identifying and investing in new growth areas, and fostering a culture that empowers our people to achieve the company’s long-term value creation goals.

“Dipti Vachani is the right leader for Adeia’s next chapter,” said Dan Moloney, chairman of the Board. “The Board’s Transition Committee conducted a rigorous search process and considered an exceptional field of candidates, and Vachani stood out for her ability to translate R&D capabilities and innovation roadmap into greater strategic relevance, new markets, stronger customer and ecosystem pull, and ultimately greater shareholder value. Our business today is positioned for continued revenue growth, led by an exceptional executive team with decades of experience and past successes. On behalf of the entire Board, I also want to thank Paul for four years of exceptional leadership and guidance; he leaves the company in a position of significant financial and strategic strength.”

“It is an honor to be chosen to lead Adeia,” said Dipti Vachani. “Adeia’s award-winning portfolio of more than 14,250 worldwide patent assets, its deep culture of invention, and the momentum the team has built provide a remarkable foundation for the company’s future. The opportunities ahead are extraordinary, from hybrid bonding and advanced thermal solutions for the AI-driven semiconductor ecosystem to new licensing frontiers across streaming, e-commerce, and automotive. I look forward to working with Adeia’s talented inventors and employees to deliver long-term value for our customers, partners, and shareholders.”

“Leading Adeia has been the greatest honor of my career, and I could not be more confident in where the company goes from here,” said Davis. “Vachani brings strong leadership experience and a history of driving growth at technology companies. With diversified revenue streams, a strengthened balance sheet, and growing opportunities in both our media and semiconductor businesses, Adeia’s future is as promising as it has ever been. I want to thank our dedicated employees and the Board, and I look forward to supporting a seamless transition.”

About Adeia 

Adeia Inc. (Nasdaq: ADEA) develops foundational innovations that shape how the world computes, connects and experiences entertainment. Its inventions span a broad range of semiconductor and media technologies, including 3D interconnect (hybrid bonding) and advanced thermal management for AI datacenters, as well as content discovery, personalization, and streaming. These inventions are licensed to leaders across the chip design and manufacturing, consumer electronics, automotive, digital entertainment, and e-commerce industries. Adeia’s innovations enable more powerful and efficient products, and more immersive, personalized experiences across billions of devices worldwide. Learn more at www.adeia.com. 

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on information available to the Company as of the date hereof, as well as the Company’s current expectations, assumptions, estimates and projections that involve risks and uncertainties. In this context, forward-looking statements often address expected future business, financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “could,” “seek,” “see,” “will,” “may,” “would,” “might,” “potentially,” “estimate,” “continue,” “target,” similar expressions or the negatives of these words or other comparable terminology that convey uncertainty of future events or outcomes. All forward-looking statements by their nature address matters that involve risks and uncertainties, many of which are beyond the Company’s control, and are not guarantees of future results.

Forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements. Important risk factors that may cause such a difference include, but are not limited to: the Company’s ability to implement its business strategy; the Company’s ability to enter into new and renewal license agreements with customers on favorable terms; the Company’s ability to retain and hire key personnel; uncertainty as to the long-term value of the Company’s common stock; legislative, regulatory and economic developments affecting the Company’s business; general economic and market developments and conditions; the Company’s ability to grow and expand its patent portfolios; changes in technology and development of new technology in the industries in which the Company operates; the evolving legal, regulatory and tax regimes under which the Company operates; unforeseen liabilities and expenses; risks associated with the Company’s indebtedness; and the unpredictability and severity of catastrophic events. These risks, as well as other risks associated with the Company’s business, are more fully discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

Contacts

Adeia Investor Relations
Chris Chaney
IR@adeia.com

Adeia Media Relations
Anna Enerio
marketing@adeia.com

Acquisition brings leading AI model research expertise to AMD, helping to shape future AI infrastructure and strengthen the open AI ecosystem

SANTA CLARA, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) — AMD (NASDAQ: AMD) today announced that it has entered into a definitive agreement to acquire World Labs, an AI model and research lab led by AI pioneer Dr. Fei-Fei Li. The acquisition will bring a world-class team of researchers and model experts to AMD, strengthening its ability to develop AI hardware, software and systems around the needs of emerging models and applications.

As AI expands into reasoning, robotics, simulation and physical AI, the demands on compute infrastructure become more diverse. World Labs’ expertise in developing advanced models will give AMD deeper insight into how workloads are evolving and help shape its future technology roadmaps. The acquisition advances AMD’s strategy to deliver AI infrastructure for an open ecosystem.

“Building the compute platforms for the next generation of AI requires a deep understanding of how models are evolving,” said Dr. Lisa Su, chair and CEO, AMD. “Fei-Fei and the World Labs team bring exceptional research leadership and model expertise. Together, we can use that insight to develop the hardware, software and systems that will power the next generation of AI and strengthen the open AI ecosystem.”

“Advancing the next generation of AI technology requires close collaboration across model research, systems and compute,” said Dr. Fei-Fei Li, co-founder and CEO, World Labs. “Joining AMD will give our team the resources and engineering depth to accelerate our research and help define the infrastructure needed for the next era of AI.”

Headquartered in San Francisco, World Labs develops spatial-intelligence models that generate, reconstruct and simulate interactive 3D environments from text, image and video inputs, as well as technology for robotic learning and simulation. Following the close of the transaction, the World Labs team will continue to focus on advancing AI model research, and Dr. Fei-Fei Li will join AMD as executive vice president and chief scientist, reporting to Dr. Lisa Su.

The all-stock transaction is valued at approximately $8.2 billion and is expected to close by the end of 2026, subject to regulatory approvals and other customary closing conditions.

About AMD  
AMD (NASDAQ: AMD) drives innovation in high-performance and AI computing to solve the world’s most important challenges. Today, AMD technology powers billions of experiences across cloud and AI infrastructure, embedded systems, AI PCs and gaming. With a broad portfolio of AI-optimized CPUs, GPUs, networking and software, AMD delivers full-stack AI solutions that provide the performance and scalability needed for a new era of intelligent computing. Learn more at www.amd.com.  

CAUTIONARY STATEMENT
This press release contains forward-looking statements concerning Advanced Micro Devices, Inc. (AMD) such as the anticipated benefits from the acquisition of World Labs by AMD and the expected timing of the closing of the acquisition, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as “would,” “may,” “expects,” “believes,” “plans,” “intends,” “projects” and other terms with similar meaning. Investors are cautioned that the forward-looking statements in this press release are based on current beliefs, assumptions and expectations, speak only as of the date of this press release and involve risks and uncertainties that could cause actual results to differ materially from current expectations. Such statements are subject to certain known and unknown risks and uncertainties, many of which are difficult to predict and are generally beyond AMD’s control, that could cause actual results and other future events to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Material factors that could cause actual results to differ materially from current expectations include, without limitation, the following: impact of government actions and regulations such as export regulations, national-security-based regulations, import tariffs, trade protection measures, and licensing requirements; competitive markets in which AMD’s products are sold; the cyclical nature of the semiconductor industry; market conditions of the industries in which AMD products are sold; AMD’s ability to introduce products on a timely basis with expected features and performance levels; loss of a significant customer; economic and market uncertainty; quarterly and seasonal sales patterns; AMD’s ability to adequately protect its technology or other intellectual property; unfavorable currency exchange rate fluctuations; ability of third party manufacturers to manufacture AMD’s products on a timely basis in sufficient quantities and using competitive technologies; availability of essential equipment, materials, components (such as memory supply), substrates or manufacturing processes; ability to achieve expected manufacturing yields for AMD’s products; AMD’s ability to generate revenue from its semi-custom SoC products; potential security vulnerabilities; potential security incidents including IT outages, data loss, data breaches and cyberattacks; uncertainties involving the ordering and shipment of AMD’s products; AMD’s reliance on third-party intellectual property to design and introduce new products; AMD’s reliance on third-party companies for design, manufacture and supply of motherboards, software, memory and other computer platform components; AMD’s reliance on Microsoft and other software vendors’ support to design and develop software to run on AMD’s products; AMD’s reliance on third-party distributors and add-in-board partners; impact of modification or interruption of AMD’s internal business processes and information systems; compatibility of AMD’s products with some or all industry-standard software and hardware; costs related to defective products; failure to maintain an efficient supply chain as customer demand changes; AMD’s ability to rely on third party supply-chain logistics functions; AMD’s ability to effectively control sales of its products on the gray market; impact of climate change on AMD’s business; AMD’s ability to realize its deferred tax assets; potential tax liabilities; current and future claims and litigation; impact of environmental laws, conflict minerals related provisions and other laws or regulations; evolving expectations from governments, investors, customers and other stakeholders regarding corporate responsibility matters; issues related to the responsible use of AI; restrictions imposed by agreements governing AMD’s notes, the guarantees of Xilinx’s notes and the revolving credit agreement; AMD’s ability to satisfy financial obligations under guarantees, leases and other commercial commitments; impact of acquisitions, joint ventures and/or investments on AMD’s business and AMD’s ability to integrate acquired businesses; impact of any impairment of the combined company’s assets; political, legal and economic risks and natural disasters; future impairments of technology license purchases; AMD’s ability to attract and retain key employees; and AMD’s stock price volatility. Investors are urged to review in detail the risks and uncertainties in AMD’s Securities and Exchange Commission filings, including but not limited to AMD’s most recent reports on Forms 10-K and 10-Q.

Contact
Brandi Martina
AMD Communications
corporate.pressinquiry@amd.com

Liz Stine
AMD Investor Relations
investor.relations@amd.com

XIAMEN, Sept. 28, 2026 (GLOBE NEWSWIRE) — STAR FASHION CULTURE HOLDINGS LIMITED (NASDAQ: STFS) (the “Company” or “STFS”) today announced the Closing of its best-efforts follow-on public offering on September 28, 2026 of 12,000,000 Class A ordinary shares at a public offering price of $0.80 per Class A ordinary share (the “Offering”).

Gross proceeds, before deducting placement agent fees and other offering expenses, are expected to be approximately $9,600,000. The Company intends to use the net proceeds of this offering for developing its online marketing services and for general administration and working capital.

Kingswood Capital Partners, LLC acted as the placement agent (the “Placement Agents”) in connection with this Offering.

The securities described above were offered pursuant to a registration statement on Form F-1, as amended (File No. 333- 298981) (the “Registration Statement”), which was declared effective by the Securities and Exchange Commission (the “SEC”) on September 24, 2026. The Offering was made only by means of a prospectus which was a part of the Registration Statement. Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Electronic copies of the final prospectus may be obtained, when available, from Kingswood Capital Partners, LLC  7280 W Palmetto Park Rd. Suite 301, Boca Raton, FL 33433, or by email at lciervo@kingswoodus.com, or by telephone at +1-800-535-6981.

This press release has been prepared for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, and no sale of these securities may be made in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s Registration Statement and other filings with the SEC, which are available for review at www.sec.gov.

About STAR FASHION CULTURE HOLDINGS LIMITED

STAR FASHION CULTURE HOLDINGS LIMITED (the “Company”) is a content marketing solutions services provider with a mission to offer high-quality diversified services. We offer services focusing on (i) marketing campaign planning and execution; (ii) offline advertising services; and (iii) online precision marketing services. We assist customers in enhancing the effectiveness of their marketing activities and the value of their brand and products through our variety of services offered. The Company first began operations in August 11, 2015 through its operating subsidiary, Xiamen Star Fashion Culture Media Co., Ltd.

For enquiry, please contact:

STAR FASHION CULTURE HOLDINGS LIMITED

12F, No.611, Sishui Road

Huli District,

Xiamen

People’s Republic of China

Tel: +86 13063138565

• DEGEVMA™ is now FDA-approved across all indications of the reference product, Xgeva^® (denosumab), to help prevent bone complications in adults with advanced cancer that has spread to the bone, for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone and for the treatment of hypercalcemia of malignancy.
• FDA approval of DEGEVMA marks another milestone in Teva’s Pivot to Growth strategy, demonstrating our ability to bring high-quality, more affordable treatment options to patients across complex therapeutic categories.
• DEGEVMA is Teva’s second FDA-approved biosimilar in 2026 and, together with PONLIMSI™ (denosumab-adet), establishes Teva’s comprehensive denosumab biosimilar portfolio across the indications of the reference products Xgeva^® and Prolia^® (denosumab).

TEL AVIV, Israel, and PARSIPPANY, N.J., Sept. 28, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved DEGEVMA™ (denosumab-adet) as a biosimilar to Xgeva^® (denosumab). DEGEVMA is indicated for the prevention of bone complications in adults with advanced cancer that has spread to the bone, for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone and for the treatment of hypercalcemia of malignancy.

The FDA approval of DEGEVMA, together with PONLIMSI (denosumab-adet), which was approved by the FDA in March 2026, establishes a comprehensive U.S. denosumab biosimilar portfolio spanning the indications of both Xgeva^® and Prolia^® (denosumab), respectively. Now, healthcare professionals and patients are able to gain expanded access to biologic treatment options in oncology-related bone disease and osteoporosis care.

“Our R&D mission is grounded in a clear commitment: translating complex biologic science into high-quality treatment options that address patient needs,” said Rob Cook, Head of Global Technical Development & Generics R&D at Teva. “The approval of DEGEVMA reflects the scientific, clinical and regulatory expertise behind our in-house biosimilars capabilities and our continued focus on expanding access to important biologic medicines.”

Biologics like denosumab represent a significant portion of healthcare expenditures, particularly in oncology. The introduction of biosimilars is critical to driving down systemic healthcare costs while broadening patient access to complex, life-enhancing medications.

“The last thing a person living with a cancer diagnosis or their families should have to worry about is access to their medicine,” said Thomas Rainey, Senior Vice President, U.S. Biosimilars at Teva. “The approval of DEGEVMA is a powerful example of Teva’s Pivot to Growth strategy in action because it represents an important step in expanding treatment options for patients and supporting healthcare systems with a high-quality biosimilar.”

The FDA approval of DEGEVMA was based on a totality of evidence, including analytical and clinical data demonstrating similar efficacy, safety and immunogenicity profile as the reference product, Xgeva^®. DEGEVMA is a human monoclonal antibody that binds to the RANKL protein, an essential regulator of osteoclast formation, function and survival. By inhibiting RANKL, DEGEVMA decreases bone resorption and cancer-induced bone destruction. The comprehensive data package submitted to the FDA demonstrated that DEGEVMA has no clinically meaningful differences from the reference product in terms of safety, purity and potency.

Teva anticipates launching DEGEVMA and PONLIMSI in the U.S. in the coming months, aligning with its broader biosimilar commercialization strategy.

DEGEVMA is currently approved in the European Union (EU). Learn more about Teva’s global biosimilars portfolio and commercialization capabilities at www.tevabiosimilars.com.

Use of Trademarks
Xgeva^® and Prolia^® are registered trademarks of Amgen, Inc.

About DEGEVMA
DEGEVMA (denosumab) is indicated for the prevention of bone complications in adults with advanced cancer that has spread to the bone, for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone and for the treatment of hypercalcemia of malignancy.

The active substance, denosumab, is a human monoclonal IgG2 antibody that targets the protein RANKL, essential for the formation, function, and survival of osteoclasts—the cells responsible for bone resorption. By binding to RANKL with high affinity and specificity, denosumab prevents the interaction between RANKL and RANK, leading to a decrease in bone resorption in cortical and trabecular bone.

DEGEVMA will be available as a 120mg/1.7mL solution for injection in a vial.

DEGEVMA is a biosimilar medicinal product, similar to the reference product Xgeva^® (denosumab), which was approved in the EU on November 18, 2025.

Comprehensive analytical, preclinical, and clinical data demonstrate that DEGEVMA has comparable quality, safety and efficacy to the reference product.

INDICATIONS
DEGEVMA is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors.

DEGEVMA is indicated for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.

DEGEVMA is indicated for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.

IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Pre-existing hypocalcemia must be corrected prior to initiating therapy with DEGEVMA.

DEGEVMA is contraindicated in patients with known clinically significant hypersensitivity to DEGEVMA or denosumab products.

WARNINGS AND PRECAUTIONS
Drug Products with Same Active Ingredient
Patients receiving DEGEVMA should not receive other denosumab products.

Hypersensitivity
Clinically significant hypersensitivity including anaphylaxis has been reported with use of DEGEVMA. Reactions may include hypotension, dyspnea, upper airway edema, lip swelling, rash, pruritus, and urticaria. If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue DEGEVMA therapy permanently.

Hypocalcemia
DEGEVMA can cause severe symptomatic hypocalcemia, and fatal cases have been reported. Correct pre-existing hypocalcemia prior to DEGEVMA treatment. Monitor calcium levels, throughout DEGEVMA therapy, especially in the first weeks of initiating therapy, and administer calcium, magnesium, and vitamin D as necessary. Concomitant use of calcimimetics and other drugs that can lower calcium levels may worsen hypocalcemia risk and serum calcium should be closely monitored. Advise patients to contact a healthcare provider for symptoms of hypocalcemia. Do not take DEGEVMA if you are allergic to denosumab or any of the ingredients of DEGEVMA.

An increased risk of hypocalcemia has been observed in clinical trials of patients with increasing renal dysfunction, most commonly with severe dysfunction (creatinine clearance less than 30 mL/min and/or on dialysis), and with inadequate/no calcium supplementation. Monitor calcium levels and calcium and vitamin D intake.

Osteonecrosis of the Jaw (ONJ)
Osteonecrosis of the jaw (ONJ) has been reported in patients receiving DEGEVMA, manifesting as jaw pain, osteomyelitis, osteitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration, or gingival erosion. Persistent pain or slow healing of the mouth or jaw after dental surgery may also be manifestations of ONJ. In clinical trials in patients with cancer, the incidence of ONJ was higher with longer duration of exposure. Patients with a history of tooth extraction, poor oral hygiene, or use of a dental appliance are at a higher risk of developing ONJ. Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections.

Perform an oral examination and appropriate preventive dentistry prior to the initiation of DEGEVMA and periodically during DEGEVMA therapy. Advise patients regarding oral hygiene practices. Avoid invasive dental procedures during treatment with DEGEVMA. Consider temporary discontinuation of DEGEVMA therapy if an invasive dental procedure must be performed.

Patients who are suspected of having or who develop ONJ while on DEGEVMA should receive care by a dentist or an oral surgeon. In these patients, extensive dental surgery to treat ONJ may exacerbate the condition.

Atypical Subtrochanteric and Diaphyseal Femoral Fracture
Atypical femoral fracture has been reported with DEGEVMA. These fractures can occur anywhere in the femoral shaft from just below the lesser trochanter to above the supracondylar flare and are transverse or short oblique in orientation without evidence of comminution.

Atypical femoral fractures most commonly occur with minimal or no trauma to the affected area. They may be bilateral, and many patients report prodromal pain in the affected area, usually presenting as dull, aching thigh pain, weeks to months before a complete fracture occurs. A number of reports note that patients were also receiving treatment with glucocorticoids (e.g., prednisone) at the time of fracture.

During DEGEVMA treatment, patients should be advised to report new or unusual thigh, hip, or groin pain. Any patient who presents with thigh or groin pain should be suspected of having an atypical fracture and should be evaluated to rule out an incomplete femur fracture. Patients presenting with an atypical femur fracture should also be assessed for symptoms and signs of fracture in the contralateral limb. Interruption of DEGEVMA therapy should be considered, pending a risk/benefit assessment, on an individual basis.

Hypercalcemia Following Treatment Discontinuation in Patients with Giant Cell Tumor of Bone and in Patients with Growing Skeletons
Clinically significant hypercalcemia requiring hospitalization and complicated by acute renal injury has been reported in DEGEVMA-treated patients with giant cell tumor of bone and patients with growing skeletons. Within the first year after treatment discontinuation, monitor patients for signs and symptoms of hypercalcemia and treat appropriately.

Multiple Vertebral Fractures (MVF) Following Treatment Discontinuation
Multiple vertebral fractures (MVF) have been reported following discontinuation of treatment with denosumab products. Patients at higher risk for MVF include those with risk factors for or a history of osteoporosis or prior fractures.

When DEGEVMA treatment is discontinued, evaluate the individual patient’s risk for vertebral fractures.

Embryo-Fetal Toxicity
Based on data from animal studies and its mechanism of action, denosumab products can cause fetal harm when administered to a pregnant woman.

Advise pregnant women and females of reproductive potential that exposure to DEGEVMA during pregnancy or within 5 months prior to conception can result in fetal harm.

ADVERSE REACTIONS
The most common adverse reactions in patients with bone metastases from solid tumors taking DEGEVMA were fatigue/asthenia, hypophosphatemia, and nausea. The most common serious side effect was dyspnea.

In patients with multiple myeloma, the most common adverse reactions were diarrhea, nausea, anemia, back pain, thrombocytopenia, peripheral edema, hypocalcemia, upper respiratory tract infection, rash, and headache. The most common serious side effect of DEGEVMA was osteonecrosis of the jaw.

To report SUSPECTED ADVERSE REACTIONS, contact Teva Pharmaceuticals at 1-888-483-8279 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see the full Prescribing Information for DEGEVMA.

About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

Teva Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “may,” “project,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully commercialize DEGEVMA (denosumab-adet) a Biosimilar to Xgeva^® (denosumab) for the prevention of bone complications in adults with advanced cancer that has spread to the bone, for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone, and for the treatment of hypercalcemia of malignancy, and PONLIMSI (denosumab-adet); our ability to successfully compete in the marketplace including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to execute on our organizational transformation and to achieve expected cost savings; and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the section captioned “Risk Factors” and “Forward-looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Teva Media Inquiries:	TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquiries:	TevaIR@Tevapharm.com

ALEXANDRIA, Va., Sept. 28, 2026 (GLOBE NEWSWIRE) — Burke & Herbert Financial Services Corp. (the “Company”) (Nasdaq: BHRB), the holding company for Burke & Herbert Bank & Trust Company (the “Bank”), today announced the pricing of its public offering of $100.0 million aggregate principal amount of its 7.00% Fixed-to-Floating Rate Subordinated Notes due 2036 (the “Notes”). The price to the public for the Notes is 100% of the principal amount of the Notes. The Notes will mature on October 1, 2036. Interest on the Notes initially will accrue at a rate equal to 7.00% per annum from and including September 30, 2026 to, but excluding, October 1, 2031, payable semiannually in arrears. From and including October 1, 2031 to, but excluding, October 1, 2036, or the earlier redemption date, interest will accrue at a floating rate per annum equal to the Three-Month Term SOFR, or other applicable Benchmark rate (as defined in the Notes), plus a spread of 222 basis points, payable quarterly in arrears. The Notes are intended to qualify as Tier 2 capital for regulatory purposes.

The offering is expected to close on September 30, 2026, subject to the satisfaction of customary closing conditions.

Beginning with the interest payment date of October 1, 2031 and on any interest payment date thereafter, the Company may, at its option, redeem the Notes, in whole or in part, at a redemption price equal to 100.00% of par, plus accrued and unpaid interest to but excluding the date of redemption. The Company may also redeem the Notes, in whole but not in part, at any time, including prior to October 1, 2031, upon the occurrence of certain specified events.

Keefe, Bruyette & Woods, A Stifel Company, acted as the sole book-running manager for the Notes offering.

The Company intends to use the net proceeds from this offering, plus cash on hand: (i) to repay $4.5 million aggregate principal amount of its outstanding 6.875% Subordinated Note, which matures on April 1, 2028 (the “2028 Note”); $18.1 million aggregate principal amount of its outstanding 6.00% Fixed-to-Floating Rate Subordinated Notes, which currently bear interest at the Three-Month Term SOFR plus 590 basis points and mature on July 1, 2030 (the “July 2030 Notes”); and $20.0 million aggregate principal amount of its outstanding 5.00% Fixed-to-Floating Rate Subordinated Notes, which currently bear interest at the Three-Month Term SOFR plus 475 basis points and mature on October 1, 2030 plus, in each case, accrued and unpaid interest; (ii) to potentially repay all or part of its outstanding $75.0 million aggregate principal amount of 3.25% Fixed-to-Floating Rate Subordinated Notes, which currently bear interest at the fixed rate of 3.25% per year and mature on December 1, 2031, plus accrued and unpaid interest; (iii) to potentially redeem all or part of its outstanding $15.0 million aggregate liquidation preference of 2021 Preferred Stock, which has dividends payable in arrears, when, as and if authorized and declared by the board of directors of the Company out of legally available funds, on a non-cumulative basis at the $10,000 per share purchase price, at an annual rate equal to 6.00%; and (iv) for general corporate purposes, including providing capital to the Bank to support its growth. A conditional notice of redemption was delivered to the holders of the Company’s July 2030 Notes with respect to the redemption of all of the outstanding principal amount of such notes. The redemption of the Company’s July 2030 Notes is contingent on this offering of the Notes and the amount of proceeds resulting from this offering. A notice of prepayment was delivered to the holder of the 2028 Note but is not contingent on this offering of the Notes.

The offering of the Notes is being made by means of a prospectus supplement and an accompanying base prospectus. The Company previously filed with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement (File No. 333-283261) and has filed a preliminary prospectus supplement to the base prospectus contained in the registration statement for the Notes to which this communication relates. The Company will file a final prospectus supplement relating to the Notes. Prospective investors should read the base prospectus contained in the registration statement, the preliminary prospectus supplement, the final prospectus supplement and the other documents the Company has filed or will file with the SEC for more complete information about the Company and the Notes offering.

Copies of these documents, when available, can be obtained for free by visiting EDGAR on the SEC’s website at www.sec.gov, or by contacting Keefe, Bruyette & Woods, Inc., toll-free at (800) 966-1559 or by emailing USCapitalMarkets@kbw.com.

No Offer or Sale

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any sale of the Notes in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offering of the Notes is being made only by means of a written prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. The Notes being offered have not been approved or disapproved by any regulatory authority, nor has any such authority passed upon the accuracy or adequacy of the registration statement, the base prospectus contained in the registration statement, the preliminary prospectus supplement or the final prospectus supplement relating thereto.

About Burke & Herbert

Burke & Herbert Financial Services Corp. is the financial holding company for Burke & Herbert Bank & Trust Company. Burke & Herbert Bank & Trust Company is the oldest continuously operating bank under its original name headquartered in the greater Washington, D.C. metropolitan area. With over 100 branches across Delaware, Kentucky, Maryland, Pennsylvania, Virginia, and West Virginia, Burke & Herbert Bank & Trust Company offers a full range of business and personal financial solutions designed to meet customers’ banking, borrowing, and investment needs. Learn more at investor.burkeandherbertbank.com.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including with respect to (or based on) the beliefs, goals, intentions, and expectations of Burke & Herbert. Forward–looking statements are typically identified by such words as “believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “forecast,” “project,” “will,” “should,” and other similar words and expressions, and are subject to numerous assumptions, risks, and uncertainties, which change over time. Additionally, forward-looking statements speak only as of the date they are made; Burke & Herbert does not assume any duty, and does not undertake, to update such forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events, or otherwise. Furthermore, because forward-looking statements are subject to assumptions and uncertainties, actual results or future events could differ, possibly materially, from those indicated in or implied by such forward-looking statements as a result of a variety of factors, many of which are beyond the control of Burke & Herbert. Such statements are based upon the current beliefs and expectations of the management of Burke & Herbert and are subject to significant risks and uncertainties outside of its control. Caution should be exercised against placing undue reliance on forward-looking statements.

Potential risks and uncertainties include, but are not limited to, the Company’s ability to complete the offering and to deploy the net proceeds of the offering as the Company currently expects. The Company cautions readers that the foregoing list of factors is not exclusive, is not necessarily in order of importance and readers should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and the Company does not intend to and, except as required by applicable law, disclaims any obligation to update or revise any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, unless required to do so under applicable securities laws.

Media Contact: Investor Relations 703-666-3555 bhfsir@burkeandherbertbank.com

Company highlights a significant institutional milestone, advancing its intended regulated-exchange uplist through institutional custody, deployed SVLT infrastructure, proprietary nanotechnology, international real-world asset initiatives and its ongoing IFRS audit programme

JOHANNESBURG, South Africa, Sept. 28, 2026 (GLOBE NEWSWIRE) — ProText Mobility, Inc. (OTC: TXTM) (“TXTM”) today issues its Inter-Quarter Shareholder Update, as referenced in the Company’s Q2 filings, highlighting significant developments in its institutional digital-asset infrastructure strategy, international relationships and expanding real-world asset (RWA) initiatives.

At the centre of this update is a development that the Company has been working toward:

ABSA BANK HAS CONFIRMED THE COMPANY’S CHAIRMAN’S PARTICIPATION AS ITS FIRST PILOT CLIENT IN ITS DIGITAL-ASSET CUSTODY ONBOARDING PROCESS.

This represents a significant milestone in TXTM’s strategy of connecting real-world assets, proprietary technology, digital tokenisation and regulated institutional financial infrastructure.

For the Company, institutional custody represents a critical component of its broader roadmap. The objective has never been simply to create digital tokens.
It has been to develop the technological, commercial and institutional infrastructure necessary to support a scalable ecosystem connecting real-world economic activity with the emerging digital financial economy.

Importantly, these developments form part of TXTM’s broader corporate strategy as the Company advances its intended UPLIST TO A REGULATED EXCHANGE.

The Company’s institutional infrastructure initiatives, ongoing IFRS audit programme, international asset development and strategic relationships are designed to strengthen its institutional readiness and support the next stage of its capital-markets evolution.

The confirmation of ABSA’s inaugural pilot relationship represents an important advancement toward that objective.

THE INSTITUTIONAL CONNECTION WE HAVE BEEN WORKING TOWARD IS NOW ESTABLISHED AT THE PILOT LEVEL.

The Company is advancing from infrastructure development toward institutional implementation, with its intended uplist remaining a central corporate objective.

1.  ABSA × RIPPLE × TXTM: A SIGNIFICANT INSTITUTIONAL MILESTONE

ABSA has directly confirmed the Company’s Chairman’s participation as its first pilot client in its digital-asset custody onboarding process.

In correspondence to the Chairman, ABSA stated:

“Your participation is helping us test and refine not only the operational aspects of the service, but also the governance, risk and compliance requirements that a regulated bank must satisfy when supporting tokenised assets.”

This confirmation is significant.

ABSA is developing the operational, governance, risk and compliance framework required to support tokenised assets within a regulated banking environment.

The Company’s inaugural pilot participation places it within that process.

The Company has already developed and deployed its SVLT tokenisation infrastructure while pursuing the institutional relationships required to support its longer-term strategy.

The ABSA pilot provides an opportunity to bring these components together.

Separately, in October 2025, Ripple announced its partnership with ABSA to provide institutional digital-asset custody technology in South Africa.

OFFICIAL ANNOUNCEMENT — ABSA AND RIPPLE:

https://ripple.com/ripple-press/ripple-expands-global-custody-footprint-into-africa-with-absa-bank/

The emerging architecture can be illustrated as follows:

RIPPLE

ABSA’s publicly announced custody technology provider.

↓

ABSA

Institutional digital-asset custody infrastructure.

↓

TXTM / SVLT

Confirmed inaugural custody pilot participation.

↓

REAL-WORLD ASSETS

Existing tokenised assets and expanding asset pipeline.

This is a conceptual architecture and does not imply a direct commercial agreement between TXTM and Ripple.

The Company distinguishes its confirmed pilot participation with ABSA from any separate commercial relationship with Ripple.

Nevertheless, the strategic significance of this development is substantial. TXTM has been building its real-world asset infrastructure.
ABSA is developing institutional custody infrastructure.

The Company’s participation in ABSA’s inaugural pilot creates an opportunity to advance the connection between these two environments.

As TXTM progresses toward its intended uplist, this institutional relationship represents an important component of its broader effort to strengthen governance, operational infrastructure and institutional readiness.

THIS IS AN IMPORTANT ENABLING MILESTONE FOR THE ROADMAP.

2.  SVLT: CONNECTING TOKENISED REAL-WORLD ASSETS WITH INSTITUTIONAL INFRASTRUCTURE

SVLT represents an important component of the Company’s developing digital-asset infrastructure.

Deployed using an ERC-3643 permissioned token architecture, SVLT incorporates identity, compliance and administrative functionality intended to support institutional requirements.

Importantly, the Company’s agricultural seed initiative has already been tokenised.

The Company’s strategy is to connect qualifying real-world assets with a framework incorporating independent verification, tokenisation, governance and institutional custody.

TXTM’S RWA INFRASTRUCTURE

REAL-WORLD ASSETS

↓

INDEPENDENT VALUATION AND VERIFICATION

↓

SVLT TOKENISATION

↓

REGULATED INSTITUTIONAL CUSTODY

↓

COLLATERAL AND FINANCIAL UTILITY

The ABSA pilot represents progress toward the institutional custody component of this architecture. The Company is continuing the applicable operational, cybersecurity and onboarding processes.
The established SVLT infrastructure provides a foundation for expanding the model to other qualifying asset classes, including the Company’s pharmaceutical-related initiatives.

Future custody services and specific financing arrangements remain subject to their applicable commercial and regulatory requirements.

Importantly, the strategy does not begin or end with a single token.

SVLT is intended to support a broader ecosystem involving multiple qualifying asset classes, projects and jurisdictions.

3.  PROPRIETARY NANOTECHNOLOGY: DEVELOPING UNDERLYING ECONOMIC VALUE

A fundamental distinction in TXTM’s strategy is the integration of its proprietary nanotechnology and associated technological capabilities with its developing RWA infrastructure.

The Company is pursuing opportunities to apply these capabilities across qualifying commercial sectors, including agriculture and environmental applications.

The strategic objective is to develop measurable economic value that can subsequently qualify for digital representation and institutional financial applications.

THE COMPANY’S INTENDED MODEL:

PROPRIETARY TECHNOLOGY

↓

ECONOMIC ACTIVITY

↓

MEASURABLE ASSETS

↓

INDEPENDENT VERIFICATION

↓

TOKENISATION

↓

INSTITUTIONAL CONNECTIVITY

This creates the potential for an expanding asset pipeline.

As additional technologies, projects and commercial applications demonstrate independently supportable economic value, the Company intends to evaluate their eligibility for inclusion within its broader RWA ecosystem.

The Company recognises that technological potential does not automatically establish recognised balance-sheet value or tokenisation eligibility.

Commercialisation, appropriate accounting treatment, legal rights, independent valuation and verification remain essential.

The integration of proprietary technology with institutional digital-asset infrastructure represents an important element of TXTM’s long-term strategy.

4.  BRICS 2026, AfCFTA, CARICOM AND GRULAC: BUILDING INTERNATIONAL RELATIONSHIPS

The Company’s Chairman recently returned from India following his participation in BRICS 2026-related engagements.

These activities form part of the Company’s continuing efforts to establish international relationships and identify opportunities connecting real-world economic development with institutional financial infrastructure.

During his visit, the Chairman also met with His Excellency Jason Hall, Jamaica’s High Commissioner to India.

These engagements complement the Company’s broader relationship-building activities across Africa, BRICS economies, the Caribbean and Latin America.

The Company recognises the importance of the African Continental Free Trade Area (AfCFTA), the Caribbean Community (CARICOM) and the United Nations Group of Latin American and Caribbean Countries (GRULAC) within the wider economic and diplomatic landscape.

Together, these regions represent substantial opportunities involving agriculture, energy, natural resources, environmental infrastructure, technology and international trade.

The Company’s objective is to develop commercially viable relationships and identify qualifying projects across these markets.

These international engagements do not constitute commercial agreements with the regional organisations themselves.

Rather, they provide important context for the Company’s developing international strategy.

DIFFERENT MARKETS. DIFFERENT RESOURCES. ONE INCREASINGLY CONNECTED ECONOMIC LANDSCAPE.

5.  VENEZUELA: A CIRCULAR AGRICULTURAL AND ENERGY INFRASTRUCTURE OPPORTUNITY

The Company is advancing its Venezuela initiative, which involves a signed government pilot.

The proposed initiative introduces a circular agricultural infrastructure model connecting food production with potential renewable energy, resource recovery and environmental value creation.

The proposed process incorporates rice production, agricultural residue recovery, suitable biomass processing, biogas generation, renewable power and heat, and potential fertilizer and water recovery.

Subject to engineering and commercial feasibility, renewable electricity may also support future green-hydrogen production.

VENEZUELA: PROPOSED INTEGRATED VALUE CHAIN

01 — RICE PRODUCTION

02 — AGRICULTURAL RESIDUES

03 — BIOGAS GENERATION

04 — RENEWABLE POWER AND HEAT

05 — FERTILIZER AND RESOURCE RECOVERY

06 — POTENTIAL GREEN HYDROGEN

07 — POTENTIAL VERIFIED ENVIRONMENTAL ATTRIBUTES

Environmental attributes remain subject to eligible methodologies, independent verification and measurement, reporting and verification requirements.

The broader objective is to demonstrate how integrated agricultural infrastructure can create multiple measurable economic value streams.

Engineering feasibility, regulatory approvals, independent verification and project financing will determine which components can be commercially implemented.

Qualifying economic assets and contractual rights arising from such projects may subsequently be evaluated for inclusion within the Company’s RWA strategy.

6.  BRIGHTLY VENTURES AND B TERRA CORP: EXPANDING THE REAL-WORLD ASSET PIPELINE

The Company’s strategic relationships with Brightly Ventures and B Terra Corp represent additional elements of its developing ecosystem.

BRIGHTLY VENTURES

The Brightly relationship introduces opportunities involving environmental measurement, data infrastructure, verification and the development of qualifying environmental assets.

Measurement and independent verification are fundamental to establishing credible environmental economic value.

The Company intends to evaluate how these capabilities may complement its broader RWA and institutional infrastructure strategy.

THE INTERNATIONAL CARBON-MARKET CONNECTION

In April 2026, Xpansiv announced its planned offering of Brightly’s food-waste methane-reduction carbon credits through its CBL exchange.

The announcement identified an initial offering of approximately 250,000 ex-ante credits, with potential expansion to 500,000.

OFFICIAL ANNOUNCEMENT — BRIGHTLY AND XPANSIV:

https://www.xpansiv.com/news/xpansiv-to-launch-first-of-their-kind-food-waste-carbon-credits-from-brightly-on-cbl-exchange

This development is particularly relevant to the Company’s environmental and real-world asset strategy.

Separately, in October 2023, the Johannesburg Stock Exchange announced its collaboration with Xpansiv to establish an African voluntary carbon marketplace through JSE Ventures.

The marketplace provides access to international infrastructure for transactions involving qualifying carbon credits and renewable energy certificates.

OFFICIAL ANNOUNCEMENT — JSE AND XPANSIV:

https://www.jse.co.za/news/news/jse-collaborates-xpansiv-launch-voluntary-carbon-market-advance-south-africas-carbon

These independently announced developments demonstrate how environmental projects, carbon-market infrastructure and international financial markets are becoming increasingly connected.

They also provide relevant market context for TXTM’s broader RWA strategy and international ambitions.

Brightly’s announced relationship with Xpansiv and the JSE’s separate collaboration with Xpansiv do not constitute direct agreements between TXTM and those market operators.

Nevertheless, the developments illustrate a broader opportunity to connect independently verified environmental assets with established international market infrastructure.

B TERRA CORP

The Company’s strategic letter of intent with B Terra Corp introduces another potential component of its developing real-world asset pipeline.

Both relationships remain subject to their respective commercial milestones and definitive arrangements where applicable.

The Company’s objective is to develop a diversified ecosystem involving independently supportable assets, multiple commercial applications and appropriate institutional infrastructure.

7.  NATIVE NATIONS, INDIGENOUS ECONOMIES AND JURISDICTIONAL SOVEREIGNTY

South Africa’s Heritage Day, celebrated on September 24, provides an appropriate occasion to recognise the relationship between heritage, economic development and the stewardship of real-world resources.

The ancient Khoisan peoples of Southern Africa form an important part of this heritage.

The Company’s engagement with Native Nations introduces another dimension to its international strategy.

TXTM is exploring how modern digital infrastructure may interact with indigenous economic development while respecting the distinct legal, governmental and sovereign frameworks of participating communities.

Potential applications may include agriculture, natural resources, renewable energy, environmental stewardship, infrastructure, intellectual property and community enterprises.

Every jurisdiction and participating Native Nation has its own legal and governmental framework.

Any future initiative must respect applicable indigenous rights, land rights, governmental authority, legal requirements and community decision-making processes.

TECHNOLOGY MUST SERVE PEOPLE AND THEIR JURISDICTIONS — NOT REPLACE THEM.

This principle remains central to the Company’s approach.

8.  AN INCREASINGLY CONNECTED GLOBAL RWA ARCHITECTURE

The Company’s individual initiatives are designed to contribute to a broader strategic architecture.

TXTM’S DEVELOPING ECOSYSTEM

PROPRIETARY TECHNOLOGY

Nanotechnology and related opportunities for economic development.

REAL-WORLD ASSET DEVELOPMENT

Venezuela, Brightly, B Terra and other potential qualifying international projects.

SVLT INFRASTRUCTURE

Permissioned tokenisation, identity, compliance and asset administration.

INSTITUTIONAL CUSTODY

ABSA’s confirmed inaugural pilot participation and associated onboarding processes.

INTERNATIONAL CONNECTIVITY

Developing relationships across Africa, BRICS economies, the Caribbean, Latin America and Native Nations.

These initiatives involve different assets, jurisdictions, commercial arrangements and stages of development.

The Company’s objective is to connect qualifying opportunities through a common framework incorporating technology, governance, verification, compliance and institutional infrastructure.

The ABSA pilot represents an important milestone within that architecture.

Together, these initiatives are intended to strengthen the Company’s institutional foundation as it advances its proposed regulated-exchange uplist.

9.  THE NEXT PHASE: INSTITUTIONAL IMPLEMENTATION AND TXTM’S UPLIST STRATEGY

With the inaugural ABSA pilot relationship confirmed, the Company is advancing the next phase of its roadmap.

Its priorities include:

• Progressing ABSA’s applicable custody onboarding, cybersecurity and operational requirements.
• Advancing SVLT’s institutional governance, compliance and asset administration infrastructure.
• Continuing the Company’s IFRS audit and financial reporting programme.
• Developing qualifying assets and commercial opportunities through its existing strategic relationships.
• Advancing the Company’s intended regulated-exchange uplist strategy and evaluating appropriate institutional financing pathways.

STRENGTHENING THE FINANCIAL FOUNDATION FOR UPLISTING

TXTM’s voluntary financial reporting programme represents another important component of its institutional-readiness strategy.

The Company has completed its 2022 and 2023 audits and is advancing its 2024 and 2025 IFRS audit programme.

Its existing Canadian engagement forms part of the next stage of its international financial reporting preparations.

This programme extends beyond the general independent-audit requirements applicable to qualifying OTCID issuers under the OTC Markets Alternative Reporting Standard.

In addition to improving international comparability, the programme provides an opportunity to establish the appropriate IFRS treatment of qualifying agricultural, pharmaceutical and other assets, including applicable foreign-currency translation effects.

The Company recognises that IFRS asset measurement and currency translation are distinct accounting considerations.

Their actual effects on reported assets, profit and shareholders’ equity will depend on the applicable accounting requirements and completed independent audits.

These initiatives are intended to support institutional due diligence, the Company’s planned regulated-exchange uplist and the continued development of long-term franchise value.

ADVANCING THE COMPANY’S REGULATED-EXCHANGE UPLIST

The Company’s intended uplist remains a central objective of its corporate strategy.

TXTM’s roadmap is designed to support its progression toward regulated-exchange listings and expanded participation in institutional capital markets.

The Company continues developing the financial reporting, corporate governance, institutional infrastructure and strategic relationships necessary to support that objective.

Its ongoing IFRS audit programme, proprietary technologies, SVLT infrastructure, developing real-world asset pipeline and institutional relationships represent complementary components of this strategy.

The objective is to establish a stronger institutional foundation, expand access to regulated capital markets and create opportunities for broader investor participation.

The Company will continue evaluating suitable exchange pathways, transaction structures and applicable regulatory requirements.

THE JSE: AN ADDITIONAL INTERNATIONAL CAPITAL-MARKETS OPPORTUNITY

In October 2022, the New York Stock Exchange and Johannesburg Stock Exchange announced an agreement concerning collaboration on dual listings.

The agreement also included exploration of opportunities involving ESG, exchange-traded funds and digital assets.

NYSE–JSE COLLABORATION:

https://www.businesswire.com/news/home/20221010005789/en/The-New-York-Stock-Exchange-and-The-Johannesburg-Stock-Exchange-Announce-Collaboration-on-Dual-Listings

This is particularly relevant to TXTM’s broader international strategy and its developing environmental and real-world asset initiatives.

In addition, the JSE’s revised listing requirements provide an expanded fast-track secondary-listing framework, including a 12-month minimum primary-listing period on an approved exchange.

OFFICIAL JSE FAST-TRACK SECONDARY-LISTING ANNOUNCEMENT:

https://www.jse.co.za/news/news/fsca-greenlights-jse-simplification-project

Following a successful qualifying primary uplist, TXTM intends to evaluate a potential secondary listing on the JSE.

Any such listing would remain subject to the Company’s primary listing venue, applicable eligibility requirements, regulatory approvals and completion of the necessary processes.

These exchange-level developments are not agreements with TXTM.

They nevertheless provide an established international regulatory and market framework relevant to the Company’s longer-term strategy.

THE ROADMAP TO UPLIST

INSTITUTIONAL READINESS

↓

STRONGER GOVERNANCE AND FINANCIAL REPORTING

↓

VERIFIED REAL-WORLD ECONOMIC VALUE

↓

REGULATED-EXCHANGE UPLIST

↓

LONG-TERM SHAREHOLDER VALUE

These are strategic objectives, not completed milestones or assured outcomes.

THE OBJECTIVE: INSTITUTIONAL READINESS, REGULATED MARKET ACCESS AND LONG-TERM SHAREHOLDER VALUE.

Institutional custody represents a key enabling component of the Company’s strategy.

The Company will continue evaluating institutional financing opportunities and intends to provide further shareholder updates as material milestones are achieved.

Any proposed uplist remains subject to applicable exchange listing standards, financial and governance requirements, regulatory approvals and completion of the relevant processes.

FROM INFRASTRUCTURE DEVELOPMENT TO INSTITUTIONAL IMPLEMENTATION. FROM INSTITUTIONAL IMPLEMENTATION TOWARD A REGULATED-EXCHANGE UPLIST. THE ROADMAP IS MOVING.

10.   MESSAGE FROM THE CHAIRMAN

Dr. Ahmed Jamaloodeen, Chairman of ProText Mobility, Inc., stated:

“Our shareholders have remained with us as we have pursued a strategy extending beyond any single technology, asset class, financial institution or jurisdiction.

“We recognised early that meaningful real-world asset tokenisation would require more than blockchain technology.

“It would require real assets, independently supportable valuations, governance, regulatory compliance, institutional relationships and appropriate custody infrastructure.

“ABSA’s confirmation of our inaugural pilot participation represents an important milestone in that journey.

“One of the key institutional relationships we have been working toward is now established at the pilot level.

“This enables us to advance the next phase of our strategy, connecting proprietary technology, real-world economic development and institutional financial infrastructure.

“Our intended uplist remains a central objective of our corporate strategy.

“Our IFRS audit programme, proprietary technology, international initiatives, SVLT infrastructure and ABSA custody pilot are components of this broader strategy.

“We are voluntarily investing in international financial reporting standards and developing the institutional foundations necessary to support our future.

“Our objective is to establish an institutional foundation capable of supporting our intended uplist and creating sustainable long-term value for our shareholders.

“The roadmap is not simply about tokenisation. It is about strengthening our institutional infrastructure, developing independently supportable economic value and advancing the Company’s capital-markets strategy.

“Our focus remains on governance, compliance, verification, custody, jurisdiction, scalability and execution.

“We thank our shareholders for their continued patience, confidence and support.

“THE ROADMAP IS MOVING.”

11.   HERITAGE, RESONANCE AND OUR SHARED FUTURE

The Company’s international vision recognises that meaningful economic development must respect the people, communities, cultures and jurisdictions that create and sustain real-world value.

As South Africa celebrates its heritage, TXTM recognises the importance of building economic relationships across cultures and borders.

The Company’s guiding philosophy remains: 432 Hz

RESONANCE → ALIGNMENT → EXECUTION

SIMUNYE

WE ARE ONE.

Different countries. Different cultures. Different jurisdictions. Different assets. Different technologies.

ONE INCREASINGLY CONNECTED VISION.

From heritage to real-world value.

From real-world value to institutional infrastructure.

From institutional infrastructure toward a regulated-exchange uplist. From institutional infrastructure to the digital economy.

THE ROADMAP IS MOVING.

ABOUT PROTEXT MOBILITY, INC.

ProText Mobility, Inc. is pursuing a strategy involving proprietary technology, real-world assets, digital tokenisation and institutional financial infrastructure.

The Company’s roadmap incorporates international relationship development and opportunities to connect qualifying economic assets with compliant digital financial infrastructure.

The Company is advancing an intended regulated-exchange uplist strategy, supported by its ongoing financial reporting programme, institutional infrastructure development and broader real-world asset initiatives.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements, including statements concerning the Company’s business strategy, proposed projects, tokenisation infrastructure, commercial relationships, potential financing arrangements, regulatory processes, intended uplist and anticipated developments.

These statements involve risks and uncertainties, and actual results may differ materially from those expressed or implied.

Pilot participation does not guarantee commercial custody services, institutional financing, asset eligibility, liquidity, exchange-listing approval or future revenue.

Proposed transactions and initiatives may require additional agreements, independent verification, regulatory approvals and financing.

The Company’s intended uplist is subject to applicable exchange-listing standards, financial and corporate governance requirements, regulatory processes and other relevant conditions.

The possibility of a subsequent JSE listing would introduce further eligibility requirements and approvals.

No assurance can be given that a proposed uplist will be completed or that any particular exchange will approve the Company’s securities for listing.

The Company undertakes no obligation to update forward-looking statements except as required by applicable law.

INVESTOR RELATIONS & MEDIA CONTACT

Mr. Dylon Du Plooy
Chief Executive Officer Email: dylon@rsammd.co.za
X: https://x.com/MrDylonDuPlooy
Executive profile: https://protxtm.com/mr-d-du-plooy-ceo/

Dr. Ahmed Jamaloodeen (Dr. J)
President & Chairman Email: exportintl@aol.com
X: https://x.com/Dr_Jamaloodeen
Executive profile: https://protxtm.com/dr-a-jamaloodeen-md-chairman/

Company Website: https://protxtm.com/
Investor Relations: https://protxtm.com/investor-relations/

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/85847555-2fbd-44b0-894b-325fe40c75ce